Dyne Therapeutics (NASDAQ:DYN) Given New $46.00 Price Target at HC Wainwright

Dyne Therapeutics (NASDAQ:DYN - Free Report) had its target price reduced by HC Wainwright from $55.00 to $46.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Dyne Therapeutics' Q1 2025 earnings at ($0.90) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.91) EPS and FY2029 earnings at $1.56 EPS.

A number of other research analysts have also recently commented on DYN. Baird R W upgraded Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Chardan Capital reiterated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Friday, January 10th. Finally, Raymond James upgraded Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $48.64.

Remove Ads

Dyne Therapeutics Trading Down 3.5 %

DYN stock traded down $0.43 during midday trading on Friday, reaching $11.89. The stock had a trading volume of 3,031,714 shares, compared to its average volume of 2,283,026. Dyne Therapeutics has a 52-week low of $11.62 and a 52-week high of $47.45. The company's fifty day simple moving average is $16.75 and its 200 day simple moving average is $27.26. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -3.34 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. Sell-side analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Buying and Selling

In related news, SVP Richard William Scalzo sold 1,455 shares of the firm's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the sale, the senior vice president now owns 127,078 shares in the company, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares in the company, valued at $5,671,382.20. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,387 shares of company stock worth $142,789 in the last 90 days. Company insiders own 20.77% of the company's stock.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently modified their holdings of DYN. Quantbot Technologies LP purchased a new position in Dyne Therapeutics in the third quarter worth $34,000. Point72 DIFC Ltd purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter worth $36,000. US Bancorp DE grew its stake in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock worth $49,000 after purchasing an additional 1,212 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Dyne Therapeutics in the 4th quarter valued at about $50,000. Finally, KBC Group NV lifted its stake in shares of Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after purchasing an additional 751 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.